Intellia Therapeutics, Inc. (NASDAQ:NTLA) CEO Sells $326,509.26 in Stock

Intellia Therapeutics, Inc. (NASDAQ:NTLA) CEO John M. Leonard sold 26,807 shares of the business’s stock in a transaction on Friday, January 3rd. The stock was sold at an average price of $12.18, for a total transaction of $326,509.26. Following the sale, the chief executive officer now directly owns 941,115 shares in the company, valued at approximately $11,462,780.70. The trade was a 2.77 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Intellia Therapeutics Price Performance

Shares of NTLA stock traded down $0.33 on Tuesday, reaching $12.47. 2,355,020 shares of the company were exchanged, compared to its average volume of 2,637,028. The company has a 50-day moving average of $14.01 and a 200-day moving average of $19.28. Intellia Therapeutics, Inc. has a one year low of $11.34 and a one year high of $34.87. The company has a market cap of $1.27 billion, a price-to-earnings ratio of -2.29 and a beta of 1.83.

Intellia Therapeutics (NASDAQ:NTLA) last released its quarterly earnings data on Thursday, November 7th. The company reported ($1.34) earnings per share for the quarter, topping the consensus estimate of ($1.37) by $0.03. The business had revenue of $9.10 million for the quarter, compared to analyst estimates of $8.28 million. The business’s quarterly revenue was down 24.1% on a year-over-year basis. During the same quarter in the previous year, the company posted ($1.38) EPS. As a group, sell-side analysts predict that Intellia Therapeutics, Inc. will post -5.12 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on the company. Wells Fargo & Company lowered their target price on Intellia Therapeutics from $80.00 to $70.00 and set an “overweight” rating for the company in a report on Monday, November 18th. Wedbush reissued a “neutral” rating and set a $14.00 target price on shares of Intellia Therapeutics in a report on Monday, November 18th. The Goldman Sachs Group cut their price target on shares of Intellia Therapeutics from $31.00 to $20.00 and set a “neutral” rating on the stock in a report on Friday, October 25th. StockNews.com upgraded Intellia Therapeutics to a “sell” rating in a report on Friday, November 8th. Finally, Robert W. Baird reduced their target price on Intellia Therapeutics from $24.00 to $18.00 and set a “neutral” rating on the stock in a report on Friday, October 25th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $54.94.

Institutional Investors Weigh In On Intellia Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of NTLA. ARK Investment Management LLC raised its holdings in shares of Intellia Therapeutics by 5.7% in the third quarter. ARK Investment Management LLC now owns 12,255,440 shares of the company’s stock valued at $251,849,000 after purchasing an additional 659,651 shares during the last quarter. State Street Corp increased its holdings in Intellia Therapeutics by 17.9% in the 3rd quarter. State Street Corp now owns 5,143,534 shares of the company’s stock worth $105,700,000 after acquiring an additional 780,754 shares during the last quarter. Geode Capital Management LLC raised its position in shares of Intellia Therapeutics by 2.2% in the third quarter. Geode Capital Management LLC now owns 2,343,310 shares of the company’s stock valued at $48,164,000 after purchasing an additional 49,367 shares during the period. FMR LLC boosted its holdings in shares of Intellia Therapeutics by 5.0% in the third quarter. FMR LLC now owns 2,339,522 shares of the company’s stock worth $48,077,000 after acquiring an additional 111,104 shares during the period. Finally, Federated Hermes Inc. grew its holdings in Intellia Therapeutics by 19.2% during the 2nd quarter. Federated Hermes Inc. now owns 2,300,889 shares of the company’s stock valued at $51,494,000 after buying an additional 371,189 shares in the last quarter. 88.77% of the stock is owned by hedge funds and other institutional investors.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.